Maoxiang Group Co., Ltd. was founded in 1984. After years of unremitting efforts, the company has developed into a diversified group enterprise with a main focus on medicine, and also engaged in real estate, wine and other production, with a total assets of 1.25 billion yuan. The group covers an area of ​​650,000 square meters, has a total construction area of ​​55,000 square meters, and has nearly 5,000 employees. The market network is spread all over the country. The group consists of Tonghua Maoxiang Pharmaceutical Co., Ltd., Tonghua Maoxiang Pharmaceutical Co., Ltd., Maoxiang Group (Changchun) Pharmaceutical Co., Ltd., Maoxiang Group (Jilin) ​​Pharmaceutical Co., Ltd., Jilin Xianghe Real Estate Development Co., Ltd., Tonghua Maoxiang Wine Co., Ltd., Tonghua Xinhua Color Printing Factory and other subsidiaries.

Over the years, Maoxiang Group Co., Ltd. has been committed to the principle of pioneering, enterprising and realistic innovation, and has been operating independently and developing independently for the society and the people, focusing on product development, and adhering to the principle of "creating health, maintaining health and creating for life." The concept of miracle, adhere to scientific and technological innovation, and scientific and technological investment reaches more than 15% of annual sales revenue, accelerate the transformation of results and the industrialization of new drugs, base itself on medicine, and continuously enhance the core competitiveness of the pharmaceutical industry, so that the economic development of Maoxiang Group will be presented The gratifying momentum of a virtuous cycle. The group has many pharmaceutical production lines such as injection antibiotic powder injections, solid preparations, liquid preparations, etc. designed according to national GMP standards, and can produce chemical synthetic raw materials and capsules (including sustained release agents, controlled release preparations), tablets (including 289 varieties of 13 dosage forms, including 13 dosage forms, including granules, powder injections, water injections, soft capsules, drops, oral liquids, syrups, ointments, suppositories, and honey pills. The company produces series of traditional Chinese and Western medicine products Tektronix, Jinfukang, Anshen Capsules, Xiantai, Pushu, etc. for its good therapeutic effects and has won the recognition of patients and has become a well-known domestic brand. In 2002, Maoxiang Group independently developed and developed the new national first-class anti-cancer drug chloroxyquine for nearly 18 years. It obtained the invention patent certificate issued by the State Intellectual Property Office and obtained the new drug certificate issued by the State Food and Drug Administration in April 2003. Production approval documents, this product has a definite efficacy in breast cancer, non-small cell lung cancer, etc. After the drug is put into production and market, it will improve the quality of life and quality of life of cancer patients and bring good news to cancer patients. In addition, the group has approved four national Class I new drugs and four national Class I new drugs under development.